Showing papers in "International Journal of Surgery in 2022"

TL;DR: Wang et al. as discussed by the authors established a novel cell death index (CDI) model by comprehensively analyzing diverse cell death patterns, which can accurately predict clinical prognosis and drug sensitivity of TNBC after surgery.

TL;DR: Tislelizumab plus chemotherapy as neoadjuvant therapy demonstrates promising antitumor activity for resectable esophageal squamous cell carcinoma (ESCC) with high rates of MPR, pCR, and R0 resection, as well as acceptable tolerability as mentioned in this paper .

TL;DR: The present provides updated information on clinical management, antiviral drugs, immunotherapeutics and prospective aspects for treating monkeypox.

TL;DR: Wang et al. as mentioned in this paper provided a viewpoint on the prominent characteristics of the SARS-CoV-2 genomes and discuss the situations that might have resulted in their evolution so that we can be better prepared to understand, predict and possibly avert such future happenings.

TL;DR: In this article , the potential benefits behind using bovine-derived antibodies and camelid-derived nanobodies in countering SARS-CoV-2 and its emerging variants and mutants are discussed.

TL;DR: In this article , a systematic screening for articles focusing on the efficacy and safety of neoadjuvant immunotherapy in locally advanced and surgically resectable esophageal cancer (EC) was performed using PubMed, Embase, Web of Science and international tumor congresses.

TL;DR: In this paper , a review of nanoparticles-based drug delivery systems for the treatment of COVID-19 to increase the bioavailability of current drugs, reduce their toxicity, and to increase their efficiency is presented.

TL;DR: In this paper , the authors compared oncological outcomes in patients undergoing ablative therapies (AT) or partial nephrectomy (PN) for T1a or T1b SRM.